Romyelocel-L

N/A

Report date: 2023/02/17 21:06:09

Base Information

Drug NameRomyelocel-L
Drug Alias NameHuman myeloid progenitor cells - Cellerant TherapeuticsCLT-008hMPC (Cellerant Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Myeloid progenitor cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsNeutropeniaMyelodysplastic SyndromesMultiple Myeloma +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCellerant Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellerant Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNeutropeniaMyelodysplastic SyndromesMultiple Myeloma +[10] 

Other Information

ATC CodeN/A
Related LinksN/A